UNSPSC 51434957: Reserpine/trichlormethiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434957 Reserpine/trichlormethiazide, a Commodity-tier code, nominally names a single pharmaceutical compound but in recent state and local solicitations captures procurement of a broader range of pharmaceutical products — primarily Advanced Life Support medications, generic multi-source pharmaceuticals, and over-the-counter products supplied to emergency medical services, public health agencies, and state employee health plans. State and local governments are buying finished pharmaceutical goods in bulk quantities for immediate operational use, with vendors required to meet strict expiration and shelf-life standards, maintain compliance with FDA and DSCSA requirements, provide Safety Data Sheets, and deliver within tight timeframes. The issuing bodies include municipal fire and rescue services (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (MMCAP, administered through state procurement offices). The code also appears in exploratory RFI activity where states are evaluating direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels.

Recent activity spans Florida, Texas, and Minnesota-anchored multi-state cooperative procurement. Tampa's City Purchasing Department posted an IFB in April 2026 for Advanced Life Support Medications (four specific line items totaling approximately 3,530 units) with delivery required within ten calendar days and a one-year contract term at an estimated value of $40,000, featuring a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in multiple states including Oregon, with products required to be available by May 15, 2026, and contracts effective July 1, 2026, using three authorized wholesalers and weighted evaluation emphasizing price competitiveness (75 percent). Texas HHS posted an RFI in early April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling state-level movement toward non-traditional pharmaceutical supply channels beyond GPOs and PBMs.